- Share Movement: Novo Nordisk (NOVO_B) shares fell about 2% following the announcement of a pricing deal on weight-loss drugs with U.S. President Donald Trump, also involving Eli Lilly (LLY).
- Analyst Commentary: TD Cowen notes the deal is “probably more negative for Novo Nordisk than not”, citing near-term challenges.
- Impact on Business:
- Short-term: Price cuts add pressure amid an already competitive market for GLP-1 weight-loss drugs.
- Medium-to-long-term: Could boost volumes if Medicare continues coverage, private insurers expand coverage, and lower out-of-pocket costs encourage patient adherence.